Dr. Robbins Facebook Live With “Hope For Migraine Community: CGRP and Emerging Treatments
A transcript of the Facebook Live video with “Hope For Migraine Community: CGRP and Emerging Treatments.
CGRP Monoclonal Antibodies for Chronic Migraine: Year One of Clinical Use
In the March 2019 issue of Practical Pain Management, Dr. Robbins shared his retrospective clinical and anecdotal experience with the new class of calcitonin gene-related peptide (CGRP) inhibitors, specifically, Aimovig (Amgen/Novartis, approved by FDA in May 2018) as a preventive for chronic migraine. That report included data over a period of six months at the Robbins Headache Clinic in Illinois. In this follow-up report, Dr. Robbins recaps six months of Aimovig use as well as three months of use with two other CGRP-inhibiting products, both approved in September 2018.
CGRP & Migraine Community
Dr. Robbins & CGRP Part I
Sometimes, when you have hundreds of thousands of people taking a medication you see different side effects than seen in clinical trials with limited participants. Since the CGRP inhibitor medications were first approved we have seen a range of side effects: constipation, increased headaches, joint pain, hair loss, higher blood pressure.
CGRP Discussion Dr. Robbins
Dr. Larry Robbins from the Robbins Headache Clinic answers questions in a Facebook Live Chat for the CGRP & Migraine Community Group. FAQs from migraine patients about the CGRP medications one year after the first one was FDA approved, and information on how clinical use experience compares to that seen in the trials.
CGRP Antagonists: Physiologic Effects and Serious Side Effects
This letter summarizes many of the clinically relevant physiologic effects of CGRP. It is important to note that much of what is published is in animal (primarily rat) studies; human studies have begun to contradict some of these results. However the human CGRP physiologic studies have not yet been published.
CGRP Monoclonal Antibodies for Chronic Migraine
Early clinical experience with Erenumab: a retrospective review
At Stake: The Possible Long-Term Side Effects of CGRP Antagonists
As AHS holds its annual meeting, very specific questions are arising about the use of CGRPs in migraine prevention. The author poses key considerations and sample cases for prescribing this new class of monoclonal antibodies.
CGRP AND SIDE EFFECTS: LETTER IN ‘HEADACHE”
Erenumab, the first of the calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) for preventing migraine, is usually referred to as “safe”…
